FinishedA randomized, open, multicenter, controlled phase III clinical trial to evaluate the safety and efficacy of recombinant human thyrotropin injection (SNA001) in post-operative debridement of patients with differentiated thyroid cancer (DTC)
Condition or disease: Differentiated Thyroid Cancer (DTC).
Phase: Phase III
Collaborators:
●Zhongshan Hospital●Tianjin Medical University General Hospital●Shanghai Tenth People’s Hospital●Sun Yat-sen University Cancer Center●Ruijin Hospital● Shanghai Jiaotong University School Of Medicine●Jilin University China Japan Union Hospital●First Hospital of Shanxi Medical University● West China Medical School●West China Hospital● Sichuan University● Hunan Tumor Hospital● Nanjing First Hospital●Shengjing Hospital affiliated to China Medical University●Affiliated Hospital of Inner Mongolia Medical College●Anhui Provincial Hospital●The First Affiliated Hospital of Zhengzhou University●The Affiliated Hospital of Southwest Medical University● Affiliated Hospital of Guilin Medical University●Zhujiang Hospital Labour Union Committee
Brief Summary:
To evaluate the efficacy of SNA001 during the radioactive iodine therapy, which is not inferior to the current thyroid hormone therapy (THW). To observe the safety and immunogenicity of SNA001 after the radioactive iodine therapy in DTC patients.